Leonardo Viana Nicacio

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company developing innovative therapies for oncology and obesity, has appointed Leonardo Viana Nicacio, M.D., as its Chief Medical Officer. 

Dr. Nicacio brings more than 20 years of pharmaceutical industry experience spanning clinical development, global medical affairs, regulatory strategy, and oncology drug commercialization.

Before joining Corbus, Dr. Nicacio served as Chief Medical Officer at Protara Therapeutics, where he led the clinical development of therapies for cancer and rare diseases. Earlier, he was Senior Vice President and Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a Menarini Group company, overseeing global development strategies for solid tumor programs.

From 2017 to 2023, Dr. Nicacio held leadership roles at Seagen, most recently as Vice President of Clinical Development. He managed development programs across multiple cancer indications, including bladder, breast, lung, gynecologic, colorectal, and head and neck cancers, and played a key role in advancing the metastatic cervical cancer therapy TIVDAK®. Earlier in his career, he held senior medical leadership positions at AstraZeneca, Flatiron Health, Sanofi, and YM Biosciences.

Dr. Nicacio earned his medical degree from the Faculdade de Ciências Médicas de Minas Gerais in Brazil and completed a molecular biology fellowship at the New York Blood Center. He is board-certified in internal medicine and medical oncology and is an active member of the American Society of Clinical Oncology and the European Society for Medical Oncology.

As Chief Medical Officer, Dr. Nicacio will oversee Corbus' clinical development strategy as the company prepares to initiate registrational studies of CRB-701 in head and neck and cervical cancers while advancing CRB-913 through its Phase 1b obesity program.